Clinical Trial Update: Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial [Phase 2]

View source ↗

Summary

Phase 2 trial (NCT04510064) evaluated camrelizumab combined with nab-POF chemotherapy in patients with initially unresectable locally advanced or limited metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Camrelizumab (camrelizumab)
• Nab-paclitaxel (paclitaxel protein-bound)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED